title: Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
abstract: Background- A reactivation of ischemia after the discontinuation of intravenous heparin in acute coronary syndromes has been described. The effect of glycoprotein IIb/IIIa blockade on heparin rebound is unknown. Methods and Results- Patients with acute coronary syndromes who received heparin therapy but not initial revascularization in the Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial were analyzed. Rates of death or myocardial (re)infarction while on heparin therapy and in 12-hour periods in the 2 days after heparin discontinuation were compared between eptifibatide and placebo. There was no difference between study groups in event rates during heparin infusion. In the 12 hours after heparin discontinuation, there was a 2.5-fold increase in all events, an 8-fold increase in death, and a 2-fold increase in myocardial infarction. However, in the 12 hours after heparin discontinuation, there was a significantly lower rate of events (1.68% versus 2.53%, P=0.03) and death (0.77% versus 0.21%, P=0.002) in the eptifibatide group compared with the placebo group. When only considering patients who were on study drug at the time of heparin discontinuation, the reduction in the combined end point was marginally significant, but the difference in the rate of death remained significant (0.68% versus 0.06%, P=0.004). In logistic regression analyses, the multivariate predictors of rebound events were the duration of heparin therapy, age, North American site, and lack of eptifibatide treatment. Conclusions- An increase in death or myocardial infarction occurs in the 12 hours after heparin discontinuation in patients with acute coronary syndromes. This rebound is attenuated by glycoprotein IIb/IIIa inhibition with eptifibatide.
authors.affiliation: Borgess Research Institute, Kalamazoo, Michigan, USA.
authors.forename: M A
authors.initials: MA
authors.lastname: Lauer
authors.forename: P L
authors.initials: PL
authors.lastname: Houghtaling
authors.forename: J G
authors.initials: JG
authors.lastname: Peterson
authors.forename: C B
authors.initials: CB
authors.lastname: Granger
authors.forename: D L
authors.initials: DL
authors.lastname: Bhatt
authors.forename: S K
authors.initials: SK
authors.lastname: Sapp
authors.forename: M L
authors.initials: ML
authors.lastname: Simoons
authors.forename: R A
authors.initials: RA
authors.lastname: Harrington
authors.forename: E J
authors.initials: EJ
authors.lastname: Topol
authors.forename: A M
authors.initials: AM
authors.lastname: Lincoff
mesh_terms: D000368:Aged; D000789:Angina, Unstable / Q000150:complications / Q000188:drug therapy / Q000401:mortality; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D004311:Double-Blind Method; D000077542:Eptifibatide; D005260:Female; D006493:Heparin / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D017202:Myocardial Ischemia / Q000188:drug therapy* / Q000209:etiology; D010455:Peptides / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D015996:Survival Rate; D013577:Syndrome
chemical_list: D000925:Anticoagulants; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D006493:Heparin; D000077542:Eptifibatide